Comparative Pharmacology
Head-to-head clinical analysis: DAYPRO ALTA versus IVRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAYPRO ALTA versus IVRA.
DAYPRO ALTA vs IVRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.
Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.
Intravenous 500 mg every 6 hours.
None Documented
None Documented
50-65 hours (mean 57 hours); clinically significant accumulation occurs with multiple dosing, requiring dose adjustment in elderly and renal impairment.
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in elderly patients.
Renal: 85% (60-90% as oxaprozin glucuronide and 5-10% as unchanged oxaprozin); Fecal: <5%; Biliary: negligible.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; fecal/biliary excretion is the primary route (60-70% as metabolites, primarily unchanged drug via bile).
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug (NSAID)
Nonsteroidal Anti-Inflammatory Drug (NSAID)